Oxford-based Orthoson raises £3.3m for back pain treatment technology

Developing an injectable bio-structural gel to restore the mechanics and biology of the intervertebral disc, Orthoson Limited offers a micro-invasive, one-session therapy for patients with low-back pain. The technology addresses degenerative disc disease by providing a conservative solution that treats both the pain and the underlying causes of degeneration.

A recent funding round saw the company raise £3.3m. This investment contributes to a total of £4.9m secured by the firm during 2026. Formal documentation for the share allotment was filed in April.

The business was incorporated in 2015 and operates from Oxford in the manufacture of medical and dental instruments and supplies. Financial records for the year ended 30 June 2025 show the company maintained a team of 18 employees. This figure is consistent with data from the firm’s professional profiles, which highlight its focus on disruptive medtech and spinal development.